Autoimmune diseases include more than 80 conditions defined by immune system dysfunction in which the body mistakenly attacks healthy tissue. Treating autoimmune and inflammatory diseases has long relied on broad-spectrum drugs that suppress the immune system. While these medications can be effective, they operate through broad immune suppression, which limits specificity and contributes to a well-documented profile of adverse effects including infection risk, long-term organ toxicity, and diminished quality of life.
In this blog, we explore how new therapies, from biologics and small molecule inhibitors to emerging CAR-T cell treatments, are reshaping the treatment landscape. We also examine the gaps still holding precision medicine back.
There is currently no cure for autoimmune and inflammatory diseases. Available treatments focus on managing symptoms, reducing inflammation, and slowing disease progression. Understanding the limitations of each approach is essential for appreciating why precision medicine represents a meaningful shift. Current treatment categories include:
Corticosteroids and disease-modifying antirheumatic drugs (DMARDs) are commonly used in combination to treat autoimmune and inflammatory diseases. Corticosteroids are often used as an additional, temporary therapy to rapidly bring down inflammation while awaiting the onset of effect from slower-acting DMARDs and limit the progression of joint damage in conditions such as RA. While these two types of immunosuppressants are some of the most commonly used treatment types, they often result in broad immune suppression and adverse side effects for patients. Importantly, not all patients respond to or tolerate DMARDs, which means a significant subset of the population remains without an effective long-term treatment option under conventional protocols.
NSAIDs can also be used for short-term symptom management to help treat the pain and inflammation caused by autoimmune and inflammatory diseases. These treatments include ibuprofen, naproxen, and meloxicam. However, they do not address the cause or biological mechanisms behind the conditions and are only effective in terms of offering short-term pain relief.
Biologic treatments consist of complex molecules produced from or containing components of living organisms. As discussed, they enable a more targeted approach than conventional immunosuppressive treatments, acting on specific components of the body’s immune system and limiting side effects. Administered via injection or intravenous infusion, these types of medications (including TNFs) have shown significant efficacy in slowing or stopping inflammation that can damage joints and organs in conditions such as arthritis and other inflammatory diseases.
However, despite offering improved patient outcomes and reduced side effects, these treatments aren’t without their risks. While more targeted, they still come with an increased risk of infection and the chance of adverse effects such as the development of other autoimmune conditions.
Several emerging approaches are beginning to shift what targeted treatment can achieve in autoimmune and inflammatory disease. Their relevance is amplified by the scale and complexity of these conditions, which continue to place significant burden on patients and healthcare systems.
Targeted synthetic DMARDs (tsDMARDs), also known as small molecule inhibitors, represent a more targeted approach to treating autoimmune rheumatic disease, with research demonstrating higher remission rates and reduced disease progression. These treatments have enabled higher rates of remission, a reduction in disease progression, and significant improvements to patients’ quality of life.
One category of tsDMARDs, Janus kinase (JAK) inhibitors, inhibit one or more JAK enzymes and help slow down the overactivity of the immune system that can lead to inflammation and pain. As of 2025, these kinds of inhibitors are the only tsDMARDs currently available for treating inflammatory arthritis.
However, while these kinds of small molecule treatments offer improved patient outcomes, they also come with an increased risk of infections including pneumonia, urinary tract infections, and cellulitis. Patients who are given these therapies require regular blood test monitoring, close follow-up, and access to prompt rheumatology advice.
CAR-T cell therapies, initially developed for cancer treatment, are now showing promise for treating B cell (white blood cell)-associated autoimmune diseases. This type of therapy involves genetically engineering a patient's T cells to express chimeric antigen receptors (CARs) which then target specific antigens associated with disease-causing cells.
Unlike some other treatment types, by directly addressing the underlying drivers of autoimmunity rather than simply managing symptoms, CAR-T therapy offers the potential for long term remission from autoimmune and inflammatory diseases. Engineered CAR-T cells also offer a highly targeted approach, enabling preservation of overall immune function and reducing the risk of infections and other side effects associated with broad immunosuppression treatments.
Early-stage clinical trials for anti-CD19 and anti-BCMA CAR-T cells have demonstrated measurable responses in patients with B cell-associated autoimmune diseases including lupus and myasthenia gravis, including sustained remission in some cases in using engineered cells to treat B cell-associated autoimmune diseases such as lupus and myasthenia gravis.
However, despite these developments and the clinical potential these treatments demonstrate, there are a number of significant safety concerns including life threatening reactions, excessive immunosuppression and the risk of secondary malignancy. Additionally, the high cost of these treatments is a prohibitive factor, with a single infusion costing between $375,000-$425,000 in the United States as of 2023.
Despite the potential of precision medicine and genetic engineering approaches, several structural barriers stand in the way of real-world adoption. Fragmented data infrastructure, inconsistent patient stratification, and evolving regulatory requirements all limit progress. The interoperability and safe sharing of data across systems and institutions is central to overcoming these barriers and addressing the heterogeneity that defines autoimmune and inflammatory conditions.
One of the major challenges in precision medicine for autoimmune and inflammatory diseases is identifying and developing patient stratification frameworks for categorizing these highly heterogeneous conditions. Many autoimmune diseases have a genetic component, with susceptibility often running in families and triggered by environmental factors in genetically predisposed individuals. This gene-environment complexity makes stratification both more difficult and more necessary. Subcategorizing patients into well-characterized groups is key to matching targeted and more effective treatment to the right individuals and identifying those who can most benefit from genetically-tailored treatments. Currently, a lack of sufficient data to validate such subgroups and cohorts is proving a challenge to developing robust stratification frameworks in these disease areas.
However, recent studies have demonstrated the potential of molecular stratification, such as grouping patients based on their transcriptomic profiles, to help identify standardized disease clusters defined by specific molecular patterns. While recent research has made progress in developing such frameworks, these approaches remain underutilized due to limited integration into clinical practice and insufficient validation in large cohorts. Collaborative, international efforts will be required to standardize stratification methods in these disease areas, as well as validate biomarkers across diverse patient populations.
With the emergence of pioneering new treatment types, such as engineered regulatory T cells, in vivo CAR-T cells and the use of CRISPR, the development of regulatory frameworks which take into account new safety, efficacy, and manufacturing standards will be crucial to delivering precision medicine treatments to market. The complexities of developing such frameworks in the rapidly changing precision medicine landscape are further compounded in the context of autoimmune and inflammatory disease, due to the diversity and intricacies of these conditions.
As new precision technologies continue to emerge, regulators and research teams will need to engage in proactive planning to ensure adaptive and timely responses to the development of these emerging treatments. Without clear policies and streamlined pathways for approval, many promising treatments face delays in getting to market.
Additionally, ethical considerations such as equitable access to advanced therapies remain unresolved. Prohibitive development costs may also result in therapies only being available in limited geographical regions and then only to patients who are able to pay for them out-of-pocket, limiting their impact on patient care.
Developing robust regulatory frameworks and policies which evolve in-step with precision medicine initiatives and technologies is therefore vital to successfully and safely delivering precision therapies to market, as well as helping to ensure equity of access.
As precision medicine technologies continue to develop, substantial investment in technical infrastructure and specialized expertise will be required to ensure effective integration into healthcare systems and the delivery of personalized treatment plans. This includes:
A unified, collaborative approach to tech and software integration, such as the integration of genetic data with electronic health records (EHRs) and specialist software systems, will be necessary to ensure equity of access and direct benefit to patients in the clinic.
Beyond the direct-to-patient clinical setting, synthetic biology and AI-driven computational approaches are being applied to accelerate target identification and biomarker discovery in autoimmune and inflammatory conditions. Such technologies have demonstrated the ability to identify disease mechanisms and biomarkers at a scale and speed that exceeds what is achievable through manual analysis, as supported by emerging research in related disease areas. These technologies may also inform diagnostic precision and accelerate the development of treatments that meaningfully alter disease trajectory for patients with complex immune conditions. Yet without consistent infrastructure, stratification and management frameworks that enable researchers to collect, integrate and validate highly heterogeneous data, technological efforts to better understand these diseases will remain limited.
Precision medicine in autoimmune and inflammatory diseases is beginning to reshape how clinicians approach treatment, diagnosis and understanding of disease mechanisms. Tailored interventions that address the complexities of these conditions can reduce the risks of broad immunosuppression, with the potential to reduce reliance on broad immunosuppression and improve both clinical outcomes and patient-reported quality of life, where supported by emerging trial data. However, the current landscape remains fragmented, with gaps in diagnostic accuracy, therapeutic targeting, and a lack of integration of emerging technologies.
The future of autoimmune and inflammatory disease treatment lies in precision, not just in science, but in the systems we build around it. From designing better tools to match the right treatment to the right patient, to ensuring those treatments are safe, accessible, and affordable, the path forward requires more than innovation alone. Precision approaches must also account for the broader biological context, including environmental triggers, microbiome dynamics, and the gene-environment interactions that shape disease onset and progression.
To fully realize the potential of precision medicine, a holistic and integrated approach is essential, one that bridges scientific innovation, clinical application, and patient-centered care through universal data standards and cross-industry collaboration. The infrastructure and frameworks built now will determine how quickly precision approaches become clinically viable at scale. That is not a scientific question alone — it is an operational and structural one, and the decisions made at the program level today will define what becomes routine practice in this therapeutic area.
Read our full whitepaper, "The future of precision medicine in autoimmune and inflammatory disease: A strategic framework," for a detailed analysis of the strategic, operational, and scientific considerations shaping this space.
For sponsors designing precision programs in autoimmune and inflammatory indications, Sano Genetics provides the patient infrastructure to support recruitment, genetic testing, and long-term engagement across these complex study designs. Get in touch to discuss how we can support your program.